ACS-MRA RFA: Understanding, Preventing and Managing Immunotherapy-related Adverse Events (irAEs) Associated with Checkpoint Inhibition for Melanoma and Other Cancers
The American Cancer Society(ACS) and Melanoma Research Alliance (MRA)have each committed $1 million for the awards. The combined $2 million will be used to fund at least one Team Award at $1 million for up to three years and up to five pilot grants at $200,000 each for two year. The purpose of this RFA is to facilitate research focused on prevention, risk, early detection and management of short and long term immune related adverse events (irAEs) associated with FDA-approved or late-stage development checkpoint cancer immunotherapies for melanoma and other cancers. This RFA will use the American Cancer Society Pilot and Exploratory Projects (PEP) award mechanism and Multidisciplinary Team Award Grant mechanism. Complete instructions on these mechanisms can be found here: Pilot and Exploratory Projects and Multidisciplinary Team Award Grant Mechanism Policies and Instructions. Deadline October 16, 2017 for Pilot Award Proposals and October 31, 2017 for Multidisciplinary Team Award Proposals.